Pharmacokinetics of Agelastatin A in the central nervous system

Zhimin Li; Takuma Kamon; David A. Personett; Thomas Caulfield; John A. Copland; Takehiko Yoshimitsu; Han W. Tun

doi:10.1039/c1md00240f

Pharmacokinetics of Agelastatin A in the central nervous system

Zhimin Li, Takuma Kamon, David A. Personett, Thomas Caulfield, John A. Copland, Takehiko Yoshimitsu, Han W. Tun

Research output: Contribution to journal › Article

11 Citations (Scopus)

Abstract

Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

Original language	English
Pages (from-to)	233-237
Number of pages	5
Journal	MedChemComm
Volume	3
Issue number	2
DOIs	https://doi.org/10.1039/c1md00240f
Publication status	Published - Feb 1 2012
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Pharmaceutical Science
Drug Discovery
Organic Chemistry

Access to Document

10.1039/c1md00240f

Fingerprint Dive into the research topics of 'Pharmacokinetics of Agelastatin A in the central nervous system'. Together they form a unique fingerprint.

Cite this

Li, Z., Kamon, T., Personett, D. A., Caulfield, T., Copland, J. A., Yoshimitsu, T., & Tun, H. W. (2012). Pharmacokinetics of Agelastatin A in the central nervous system. MedChemComm, 3(2), 233-237. https://doi.org/10.1039/c1md00240f

@article{af9f38ca70dc438982938076ce3739a0,

title = "Pharmacokinetics of Agelastatin A in the central nervous system",

abstract = "Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.",

author = "Zhimin Li and Takuma Kamon and Personett, {David A.} and Thomas Caulfield and Copland, {John A.} and Takehiko Yoshimitsu and Tun, {Han W.}",

year = "2012",

month = feb,

day = "1",

doi = "10.1039/c1md00240f",

language = "English",

volume = "3",

pages = "233--237",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of Agelastatin A in the central nervous system

AU - Li, Zhimin

AU - Kamon, Takuma

AU - Personett, David A.

AU - Caulfield, Thomas

AU - Copland, John A.

AU - Yoshimitsu, Takehiko

AU - Tun, Han W.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

AB - Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=84863149318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863149318&partnerID=8YFLogxK

U2 - 10.1039/c1md00240f

DO - 10.1039/c1md00240f

M3 - Article

AN - SCOPUS:84863149318

VL - 3

SP - 233

EP - 237

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 2

ER -